Cleveland Biolabs Inc., (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its registration statement on SEC Form S-4 (the “Registration Statement”) filed with U.S. Securities and Exchange Commission (the “SEC”) in connection with its previously announced merger with Cytocom Inc. (“Cytocom”) was declared effective by the SEC on June 10, 2021. Cytocom is a leading biopharmaceutical company creating next-generation immune therapies that deliver immune homeostasis.
A special meeting of the Cleveland BioLabs stockholders to approve the proposals related to the merger (the “Special Meeting”) will be held virtually. Details of the meeting are as follows:
Tuesday, July 6, 2021
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
10:00 a.m. ET
The Registration Statement includes a definitive proxy statement and a prospectus. Notice of the Special Meeting and the definitive proxy statement/prospectus was mailed to stockholders of the Company as of June 9, 2021.
Subsequent to the closing of the merger, the new combined company will be named “Cytocom Inc.”, and its common stock is expected to trade on the Nasdaq Capital Market under the symbol “CYTO”. The closing of the merger, which is expected to occur during the third quarter of 2021, is subject to approval by Cleveland BioLabs’ stockholders, the approval of the application for listing of the combined company’s stock on the Nasdaq Capital Market, and the satisfaction of other customary closing conditions.